ABVC Biopharma Inc (NASDAQ:ABVC) — Market Cap & Net Worth
Market Cap & Net Worth: ABVC Biopharma Inc (ABVC)
ABVC Biopharma Inc (NASDAQ:ABVC) has a market capitalization of $28.25 Million ($28.25 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24067 globally and #5187 in its home market, demonstrating a 1.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABVC Biopharma Inc's stock price $1.08 by its total outstanding shares 26654365 (26.65 Million). Also see how large is ABVC Biopharma Inc's balance sheet for a full breakdown of the balance sheet.
ABVC Biopharma Inc Market Cap History: 2016 to 2026
ABVC Biopharma Inc's market capitalization history from 2016 to 2026. Data shows change from $9.60 Billion to $28.79 Million (-49.04% CAGR). Also see ABVC Biopharma Inc (ABVC) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
ABVC Biopharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #683 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2249 of 3165 |
Weight: ABVC Biopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ABVC Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABVC Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of ABVC Biopharma Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
71.33x
ABVC Biopharma Inc's market cap is 71.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $9.60 Billion | $32.00 | -$11.01 Million | 299861273.07x | N/A |
| 2017 | $9.60 Billion | $3.20K | -$4.24 Million | 3002365.69x | N/A |
| 2018 | $9.60 Billion | $6.96K | -$5.58 Million | 1379465.32x | N/A |
| 2019 | $1.16 Billion | $701.72K | -$3.64 Million | 1659.92x | N/A |
| 2020 | $1.36 Billion | $483.05K | -$9.79 Million | 2814.17x | N/A |
| 2021 | $903.58 Million | $355.80K | -$12.84 Million | 2539.60x | N/A |
| 2022 | $166.59 Million | $969.78K | -$16.42 Million | 171.78x | N/A |
| 2023 | $30.92 Million | $152.43K | -$7.79 Million | 202.84x | N/A |
| 2024 | $15.73 Million | $509.59K | -$4.90 Million | 30.86x | N/A |
| 2025 | $56.77 Million | $795.95K | -$7.91 Million | 71.33x | N/A |
Competitor Companies of ABVC by Market Capitalization
Companies near ABVC Biopharma Inc in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of ABVC Biopharma Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ABVC Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
ABVC Biopharma Inc Historical Marketcap From 2016 to 2026
Between 2016 and today, ABVC Biopharma Inc's market cap moved from $9.60 Billion to $ 28.79 Million, with a yearly change of -49.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $28.79 Million | -49.30% |
| 2025 | $56.77 Million | +261.02% |
| 2024 | $15.73 Million | -49.14% |
| 2023 | $30.92 Million | -81.44% |
| 2022 | $166.59 Million | -81.56% |
| 2021 | $903.58 Million | -33.53% |
| 2020 | $1.36 Billion | +16.70% |
| 2019 | $1.16 Billion | -87.86% |
| 2018 | $9.60 Billion | 0.00% |
| 2017 | $9.60 Billion | 0.00% |
| 2016 | $9.60 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of ABVC Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $28.25 Million USD |
| MoneyControl | $28.25 Million USD |
| MarketWatch | $28.25 Million USD |
| marketcap.company | $28.25 Million USD |
| Reuters | $28.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II … Read more